Adaptive Biotechnologies (ADPT) News Today $6.39 +0.39 (+6.50%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $9.00December 21 at 2:53 AM | americanbankingnews.comAdaptive Biotechnologies Gains Positive Outlook with Strategic Advancements and Increased clonoSEQ UtilizationDecember 19 at 1:05 AM | markets.businessinsider.comAdaptive Biotechnologies price target raised to $9 from $8 at BTIGDecember 19 at 1:05 AM | markets.businessinsider.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 6.6% - Here's WhyDecember 18 at 5:37 PM | marketbeat.comBTIG Research Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock PriceBTIG Research lifted their price objective on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday.December 18 at 11:13 AM | marketbeat.comFmr LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Fmr LLC raised its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 102.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 233,566 shares of the company's stock after acquiring an additional 117,965 shares during the qDecember 17, 2024 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Growth in Short InterestDecember 14, 2024 | americanbankingnews.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Large Growth in Short InterestAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 9,580,000 shares, an increase of 16.8% from the November 15th total of 8,200,000 shares. Based on an average trading volume of 1,190,000 shares, the short-interest ratio is presently 8.1 days.December 14, 2024 | marketbeat.com495,492 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. bought a new stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 495,492 shares of the coDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Purchases New Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Jacobs Levy Equity Management Inc. acquired a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 143,679 shares of the compDecember 10, 2024 | marketbeat.comPier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Pier Capital LLC lifted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 20.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,275,885 shares of the company's stock after buying an additionalDecember 8, 2024 | marketbeat.comAdaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment DecisionsDecember 7, 2024 | globenewswire.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Matrix Capital Management Company LPMatrix Capital Management Company LP lessened its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 94.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 650,000 shares of the company's stock after selling 10,922,590 shareDecember 4, 2024 | marketbeat.comAdaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual MeetingDecember 3, 2024 | globenewswire.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Large Decline in Short InterestAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the target of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 8,200,000 shares, a drop of 8.5% from the October 31st total of 8,960,000 shares. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is presently 7.2 days.December 2, 2024 | marketbeat.comCerity Partners LLC Purchases 256,933 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Cerity Partners LLC raised its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 58.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 694,417 shares of the company's stock after buyinNovember 30, 2024 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by Rubric Capital Management LPRubric Capital Management LP grew its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 2.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,400,000 shares of the company's stock after buying an aNovember 27, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Lowers Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Massachusetts Financial Services Co. MA reduced its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 26.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,881,36November 27, 2024 | marketbeat.comAdaptive Biotechnologies: Making Some ProgressNovember 26, 2024 | seekingalpha.comMillrace Asset Group Inc. Acquires New Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Millrace Asset Group Inc. acquired a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 272,681 shares of the company's stock, valued at approximately $1,396,November 26, 2024 | marketbeat.comBalanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External ChallengesNovember 19, 2024 | markets.businessinsider.comWhat is William Blair's Estimate for ADPT FY2024 Earnings?Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) - Stock analysts at William Blair boosted their FY2024 EPS estimates for shares of Adaptive Biotechnologies in a report released on Thursday, November 14th. William Blair analyst A. Brackmann now anticipates that the company will post earniNovember 18, 2024 | marketbeat.comShort Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 5.5%Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 8,960,000 shares, a decrease of 5.5% from the October 15th total of 9,480,000 shares. Based on an average daily volume of 1,050,000 shares, the short-interest ratio is presently 8.5 days.November 18, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Acquires 834,253 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,733,884 shares of the company's sNovember 16, 2024 | marketbeat.comAdaptive Biotechnologies (ADPT) Receives a Buy from ScotiabankNovember 13, 2024 | markets.businessinsider.comAdaptive Biotechnologies price target raised to $7 from $6 at Piper SandlerNovember 11, 2024 | markets.businessinsider.comJ.P. Morgan Remains a Buy on Adaptive Biotechnologies (ADPT)November 11, 2024 | markets.businessinsider.comAdaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst UpgradeAdaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher Following Analyst UpgradeNovember 11, 2024 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an "overweight" rating in a research report on Monday.November 11, 2024 | marketbeat.comAdaptive Biotechnologies’ Q3 2024 Financial Performance OverviewNovember 9, 2024 | markets.businessinsider.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up Following Better-Than-Expected EarningsAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up on Earnings BeatNovember 8, 2024 | marketbeat.comAdaptive Biotechnologies sees FY MRD business revenue $143 M-$145MNovember 8, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)November 8, 2024 | markets.businessinsider.comARK Investment Management LLC Purchases 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)ARK Investment Management LLC lifted its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,601,134 shares ofNovember 8, 2024 | marketbeat.comAdaptive Biotechnologies Q3 Loss Decreases, Beats EstimatesNovember 8, 2024 | markets.businessinsider.comAdaptive Biotechnologies Reports Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comAdaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ...November 8, 2024 | finance.yahoo.comAdaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comAdaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell LymphomaNovember 7, 2024 | globenewswire.comEarnings To Watch: Adaptive Biotechnologies Corp (ADPT) Reports Q3 2024 ResultNovember 6, 2024 | finance.yahoo.comNovember 2024's Top US Penny Stocks With Growth PotentialNovember 2, 2024 | finance.yahoo.comAdaptive Biotechnologies (ADPT) Scheduled to Post Earnings on ThursdayAdaptive Biotechnologies (NASDAQ:ADPT) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=634338)October 31, 2024 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 3% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 3% - Should You Sell?October 16, 2024 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the coOctober 16, 2024 | marketbeat.comAdaptive Research Launches Decentralized Clinical Trial in Parkinson's DiseaseOctober 15, 2024 | tmcnet.comMaintaining Hold on Adaptive Biotechnologies Amidst Gradual Market Adoption and Competitive ChallengesOctober 15, 2024 | markets.businessinsider.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - Time to Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - What's Next?October 14, 2024 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Position Lifted by AQR Capital Management LLCAQR Capital Management LLC grew its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 244.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 182,076 shares of the company's stoOctober 14, 2024 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down - Time to Sell?October 10, 2024 | marketbeat.comAlgert Global LLC Sells 103,163 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Algert Global LLC lowered its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 61.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 64,323 shares of the compOctober 10, 2024 | marketbeat.com Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years. I call it my AI Retirement Playbook. I recommend you check it out now. ADPT Media Mentions By Week ADPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADPT News Sentiment▼0.920.60▲Average Medical News Sentiment ADPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADPT Articles This Week▼74▲ADPT Articles Average Week Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRISPR Therapeutics News Today Denali Therapeutics News Today Twist Bioscience News Today Vericel News Today SpringWorks Therapeutics News Today Kymera Therapeutics News Today Iovance Biotherapeutics News Today Beam Therapeutics News Today Recursion Pharmaceuticals News Today ImmunityBio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADPT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
